Ireland
--:--IST
Recruiting Phase 3

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783 · tracked via the Priya Life Science UK tracker
Sponsor
Aerogen Pharma Limited
Phase
Phase 3
Started
2025-09-24
Last updated
2026-08-06

Condition(s) studied

Respiratory Distress SyndromePre-term Infants

Investigational drug(s) / intervention(s)

APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system)Control

APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system): Subjects in the APC-0101 group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface and APC-0101 treatment will be started.

Control: Subjects in the Control group will be changed from their current nCPAP/NIV interface to the APC-0101 nCPAP/NIV interface but an empty vial will be used instead of APC-0101.

Study summary

This is a 2-part, prospective, randomized, blinded, sham-controlled, multi-center study comparing preterm subjects with RDS who are treated with APC-0101 and nCPAP/NIV to subjects treated with nCPAP/NIV alone (Sham). In Part 1, subjects will be followed until they reach 40 weeks post-menstrual age (PMA) or are discharged from the NICU, whichever comes first. In Part 2, subjects will undergo post-term follow-up through 24 months corrected age.

Eligibility

Sex
ALL
Min age
1 Hour
Max age
24 Hours
Healthy volunteers
No
Inclusion Criteria: 1. Inborn at the study site's hospital (i.e., not transferred from another hospital following delivery) 2. Gestational age at birth of 26 through 33 weeks PMA 3. Birth weight appropriate for gestational age (AGA, weight 3rd to 97th percentile on Fenton Growth Curve) 4. Birth weight ≤ 2000 grams 5. Post-natal age 1 to 24 hours at randomization 6. On nCPAP or NIV for at least 30 minutes with RSS = 1.4 - 2.0 to maintain SpO2 90-95% at randomization. RSS is calculated as (nCPAP cm H2O) × (FiO2) or as (NIV mean airway pressure cm H2O) × (FiO2). 7. FiO2 ≥ 0.24 at randomization 8. nCPAP or mPaw ≥ 6 cm H2O at randomization 9. Chest radiograph (CXR) or lung ultrasound compatible with RDS prior to randomization Exclusion Criteria: 1. On SiPAP®, RAM® cannula, or high flow nasal cannula (HFNC) (\> 2 liters per minute \[LPM\]) at the time of randomization 2. Prior instillation of surfactant 3. Premature rupture of membranes (PROM) occurring \> 14 days before birth 4. Significant congenital/chromosomal anomaly (e.g., Pierre Robin syndrome, clinically significant congenital heart disease, or trisomy) 5. Pneumothorax 6. Other etiologies of respiratory distress 7. Enrollment in another interventional study with similar efficacy endpoints 8. Apgar score at 5 min of 0-3 9. Prior cardiopulmonary resuscitation (CPR) or epinephrine 10. Base Deficit \> 15 mEq/L on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. Note that arterial blood gas is not required prior to randomization. 11. Partial pressure of carbon dioxide (PaCO2) \> 65 mmHg on most recent arterial blood gas (not capillary blood gas, venous blood gas, or cord gas) prior to randomization. 12. Triplet or higher order multiple birth

Primary outcome measure(s)

  • Failure Criteria — First 7 days of life
    Number (%) of subjects who meet the predetermined criteria for failure of nCPAP/NIV

Trial sites (12)

FacilityCityRegionStatus
University of Arkansas for Medical Sciences Little Rock Arkansas Recruiting
Jacobs Medical Center La Jolla California Recruiting
UF Health Jacksonville Jacksonville Florida Recruiting
Advent Health Orlando Florida Recruiting
Memorial Hospital of South Bend South Bend Indiana Recruiting
Goryeb Children's Hospital Morristown New Jersey Recruiting
The Trustees of Columbia University in the City of New York New York New York Recruiting
Montefiore Medical Center The Bronx New York Recruiting
Maria Farreri Children's Hospital Valhalla New York Recruiting
Christus Children's Hospital San Antonio Texas Recruiting
University of Virginia School of Medicine Charlottesville Virginia Recruiting
WVU Medicine Children's Hospital Morgantown West Virginia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06776783 on ClinicalTrials.gov ↗ ← All trials in the UK